Menu

Blog

Aug 9, 2020

The Role of Procalcitonin for Risk Assessment and Treatment of COVID-19 Patients

Posted by in category: biotech/medical

50% of people who die of covid19 have bacterial co-infections. Procalcitonin (PCT) tests may be needed to predict who will have severe infections, and how to respond with adaquate treatment. Clearly the wrong testing is being done. People need 3 tests for covid. People need antigen tests, antibody tests, and Procalcitonin (PCT) tests to see the severity of sickness a person will have.

Procalcitonin (PCT) is a widely used biomarker to assess the risk of bacterial infection and disease progression. In patients with bacterial sepsis, suspected or confirmed lower respiratory tract infections, including community-acquired pneumonia, acute bronchitis and acute exacerbations of COPD, PCT can be a useful decision-making tool for antibiotic therapy (Schuetz et al. 2018). In addition, early evidence suggests that PCT may also be a valuable tool in identifying COVID-19 patients who may be at risk for bacterial co-infection.


Procalcitonin is widely used to assess the risk of bacterial infection and disease progression. Can it be an additional tool to identify COVID-19 patients at risk of severe disease?

Comments are closed.